Picture of ACI Global logo

ACGJ ACI Global Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Momentum

Relative Strength (%)
1m-98.99%
3m-99.05%
6m-99.13%
1yr-99.14%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w Highn/a
50d MAn/a
200d MAn/a

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Margin-92.99%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Sep 200330th Sep 2004
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2003 / 2004

Blurred out image of ACI Global EPS forecast chart

Profile Summary

ACI Global Corp., formerly Par Advance Technologies Corp., a clinical-stage biopharmaceutical company engaged in the development of natural and novel peptides for the treatment or prevention of infections due to multi-drug resistant bacteria and fungi. The Company's drug candidates are proprietary synthetic and natural peptides (small proteins). Antecedents for these compounds occur in nature as part of the immune system of animals, insects and plants. Generally, the peptides bind to and kill harmful microorganisms and cancer cells. P113D, the Company's product candidate for cystic fibrosis, has been awarded Orphan Drug designation by the United States Food and Drug Administration (FDA). Demegen is also developing a novel, synthetic antimicrobial peptide in a rinse formulation for the treatment and prevention of oral candidiasis. The Company's peptide technology can also be used to prevent serious damage to crops caused by fungal and bacterial diseases.

Directors

Last Annual
September 30th, 2002
Last Interim
December 31st, 2002
Incorporated
September 16th, 1987
Public Since
April 14th, 1994
No. of Shareholders
503
No. of Employees
3
Sector
Healthcare Providers & Services
Industry
Healthcare
Exchange
us flag iconPink Sheets on Nasdaq
Shares in Issue
47,367,778
Blurred out image of a map
Address
16 N Water St # 106, GREENWICH, 06830-5834
Web
Phone
+1 2039875356
Auditors
Ernst & Young LLP

ACGJ Share Price Performance

Similar to ACGJ

Picture of 4Cable TV International logo

4Cable TV International

us flag iconPink Sheets on Nasdaq

Picture of Abattis Bioceuticals logo

Abattis Bioceuticals

us flag iconPink Sheets on Nasdaq

Picture of Accelera Innovations logo

Accelera Innovations

us flag iconPink Sheets on Nasdaq

Picture of Quantum Medical Transport logo

Quantum Medical Transport

us flag iconPink Sheets on Nasdaq

Picture of American CareSource Holdings logo

American CareSource Holdings

us flag iconPink Sheets on Nasdaq

FAQ